A Phase 4 interventional study of Fortimel in Malnutrition, Cancer and Inflammatory Bowel Diseases, sponsored by Danone Specialized Nutrition. Recruiting at 6 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-26.
Sponsored by Danone Specialized Nutrition (part of Danone) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Malnutrition by Danone — 2 open to participants now, 3 under way, none of them phase 3. Malnutrition · Danone.
Among the 12 studies in Malnutrition by Danone, this one has the largest planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2023, is the only one in phase 4, and was the 10th registered.
1,278 studies on the registry are indexed under Malnutrition; 231 are open to participants now.
Browse Malnutrition studies →2 of the 12 studies in Malnutrition by Danone are open now, in 1 country. Recruiting first, the newest first:
Nutricia Research
Ages 65+ · Healthy volunteers
By country, each count listing its studies:
Of the 150 Malnutrition studies recruiting now, 84 (56%) set no upper age limit and 44 (29%) stop at 75 or younger; 40 take children under 18; 30 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2023.
This study's planned enrollment of 140 is above the median of 119 across 844 interventional studies indexed under Malnutrition.
Median enrollment 73 across the 11 interventional studies, 228 across the 1 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Danone Specialized Nutrition, one of the names counted as Danone. Under that name alone:
Danone Specialized Nutrition is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
1 of the studies in Malnutrition by Danone that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05257980Nutricia UK LtdEvaluation of Four New Ready to Drink Oral Nutritional Supplements: Adult ONS Trial | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Malnutrition by Danone, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to compare nutritional outcomes in terms of percentage of weight gain between a new planted-based high-energy ONS and a standard high-energy ONS with animal protein (cow's mil protein) in patients at malnutrition according to Global Leadership Initiative on Malnutrition (GLIM) criteria.
Due to the increasingly pressing need to develop an oral nutritional supplement (ONS) that does not contain animal ingredients, Fortimel PlantBased, suitable for patients with Disease-Related Malnutrition or who wish to avoid or reduce the consumption of animal products for dietary or lifestyle reasons, is being promoted. At the same time, it is also a therapeutic option to be considered in the population with allergy or intolerance to cow's milk protein. Therefore, the aim is to offer an adapted therapeutic nutritional solution that guarantees nutritional results that are not inferior than ONS with animal protein (cow's milk protein).
This study was designed as an open-label randomized controlled non-inferiority trial with two arms: a new planted-based ONS (Fortimel PlantBased) as the intervention arm and standard ONS (Fortimel Energy) as the control arm, both high-energy formulas (1.5 kcal/m; 200ml).
The study will be carried out in patients at malnutrition according to Global Leadership Initiative on Malnutrition (GLIM) criteria, who need to supplement their diet by taking a high-energy ONS for at least 12 weeks. These patients will be treated and follow-up by the Endocrinology and Nutrition services of 6 public hospitals in Spain.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients ≥ 18 years old
Oncologic patients with (ECOG) 0-1
Exclusion Criteria:
Patients who need ONS due to surgical or acute illness*
Patients who have value creatinine:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Control: high-energy ONS 1.5 Kcal/m 200ml for 90 days
Dietary Supplement: Fortimel
Intervention: high-energy ONS 1.5 Kcal/m 200ml for 90 days
Dietary Supplement: Fortimel
2 bottles/day of the high energy ONS
Change in weight
Change in weight percentage
Time frame: Changes between baseline and final visit (12 weeks).
Improvement in nutritional status
Improvement in nutritional status according to the GLIM criteria. A change in classification category from grade 2 of malnutrition to grade 1 or not meet GLIM criteria, as well as a change from grade 1 to not meet GLIM criteria are considered an improvement.
Time frame: From the baseline to the final visit (12 weeks)
Change in muscle strength
Measured by dynamometry
Time frame: From the baseline to final visit (12 weeks)
Change in calf circumference
Time frame: From baseline to final visit (12 week)
Percentage of compliance
Taking into account the number of bottles per day taken, the ml of product and the ml left over.
Time frame: During the study follow up
Changes in the gastrointestinal symptom scale (GSRS)
Total score
Time frame: From the baseline to final visit (12 week)
ONS Satisfaction
Patients satisfaction taking ONS will be considered if a patient indicates a score of at least 8 points for overall satisfaction question.
Time frame: Final visit (12 week)
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2023 (actual). Primary completion is estimated for May 2024, 9 months after the start.
Of 17 phase 4 interventional studies under Malnutrition, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 49. This study's planned 9 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.